GLP-1 receptor agonists may help prevent diabetes-related lower limb events: new large U.S. database analysis finds reduced risks of lower extremity amputations, diabetic foot ulcers, and death compared with SGLT2 inhibitors in 361,000 adults with type 2 diabetes.
submitted by /u/Some-Depth924 [link] [comments]
GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients
Comments
Wegovy and Ozempic tied to dramatically lower cancer deaths – ScienceDaily
Wegovy and Ozempic tied to dramatically lower cancer deaths ScienceDaily GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients UC San Diego Today UT Health Science Center’s Liza Makowski, PhD, Helps Lead Global Conversation on GLP-1 Drugs and Cancer Risk UTHSC News Colon cancer: Can GLP-1 drugs help in lowering death rates? The Times of India […]
Could GLP-1 Drugs Make ResMed’s CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker. The company, a leading manufacturer of CPAP machines used to treat sleep apnea, faces a nuanced challenge from GLP-1-based medications. The core issue: obesity drives the vast […]
GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders
Glucagon-like peptide-1 receptor (GLP-1R) agonists have revolutionized the therapeutic landscape of diabetes and obesity, yet their therapeutic potential extends significantly further. Research using human data and animal models indicates that systemically administered GLP-1R agonists access receptors in the periphery and in the brain. The latter site of action underlies the apparent efficacy of GLP-1R agonists […]
Who’s Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Post Content
Ozempic’s Surprise Side Effect? Maybe Surviving Cancer
New research suggests that people taking GLP-1 therapy are less likely to die from colorectal cancer.
New study finds Ozempic and Mounjaro protect the heart too
New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes. Using real-world insurance data, the study found up to an 18% […]
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
Novo Nordisk released new data to underscore its pill’s safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
Is Superior Weight Loss the Most Important Outcome in Bariatric Surgery?
Treatment of obesity is undergoing a major shift with the rapid adoption and dissemination of GLP-1 receptor agonists (GLP-1 RAs). These medications have demonstrated efficacy in promoting weight loss, in addition to their role in treatment of metabolic complications such as diabetes. Importantly, these favorable outcomes have led to discussion of the role of GLP-1 […]